In a report released today, Annabel Samimy from Stifel Nicolaus maintained a Buy rating on Calliditas Therapeutics (CALT – Research Report), with a price target of $55.00. The company’s shares closed yesterday at $22.48.
According to TipRanks, Samimy is a 4-star analyst with an average return of 5.7% and a 45.86% success rate. Samimy covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, Inventiva, and Cara Therapeutics.
Calliditas Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $40.94, representing an 82.12% upside. In a report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $44.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
CALT market cap is currently $586.6M and has a P/E ratio of -14.16.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Calliditas Therapeutics (CALT) Company Description:
Calliditas Therapeutics AB operates as a specialty pharmaceutical company in Sweden. The company is engaged in the provision of pharmaceutical products for patients with niche indications. It is focused on the development and commercialization of the product candidate Nefecon intended for the treatment of patients with the inflammatory renal disease IgA nephropathy, a disease that causes chronic inflammation of the kidneys.
Read More on CALT:
